Additional prospective studies of CD19 CAR-T agents tisagenlecleucel (NCT04134117) and axicabtagene ciloleucel (NCT04608487) are underway in patients with CNS lymphoma, with results eagerly awaited. The gene discussed is CD19; the disease is primary central nervous system lymphoma.